Corrigendum to “Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer” [Lung Cancer 69S1 (2010) S4–S10] (Lung Cancer (2010) 69S1(S4–S10) (S016950021070132X), (10.1016/S0169-5002(10)70132-X));Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer

Lung Cancer

Volumn 69, Issue SUPPL. 1, 2010, Pages S4-

  Nuijten, Mark ^a   Heigener, David F ^b   Bischoff, Helge G ^c   Chouaid, Christos ^d   Vergnenègre, Alain ^e   de Castro Carpeño, Javier ^f   Aultman, Rick ^g   Walzer, Stefan ^h,i   Siebert, Uwe ^h,i  

^a Ars Accessus Medica   (Netherlands)

^b KRANKENHAUS GROSSHANSDORF   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d HÔPITAL SAINT ANTOINE   (France)

^e LIMOGES UNIVERSITY HOSPITAL   (France)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

^h UNIVERSITY FOR HEALTH SCIENCES   (Austria)

ⁱ HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Bevacizumab; Effectiveness; Indirect comparison; Markov model; Non small cell lung cancer (NSCLC); Pemetrexed

Indexed keywords

BEVACIZUMAB; CISPLATIN; GEMCITABINE; PEMETREXED;

ADVANCED CANCER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; MORTALITY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 77956035404     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/S0169-5002(10)70136-7     Document Type: Erratum

References (25)

1. Sant M, Aareleid T, Berrino F, Bielska LM, Carli PM, Faivre J, et al. EUROCARE-3: survival of cancer patients diagnosed 1990 94 results and commentary. Ann Oncol 2003, 14(Suppl 5):v61-118.
2. Wilking N, Högberg D, Jönsson B. Benchmarking report of lung cancer care in selected European Countries. Karolinska Institutet/i3 Innovus, Stockholm School of Economics, 2008.
3. Toloza EM, Harpole L, McCrory DC Noninvasive staging of non- small cell lung cancer: a review of the current evidence. Chest 2003, 123(Suppl 1):137S-146S.
4. Wilking N, Jönsson B. A pan-European comparison regarding patient access to cancer drugs. Karolinska Institutet in collaboration with Stockholm School of Economics, Stockholm, Sweden. 2005 Sept 7.
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346(2):92-98.
6. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non- small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
7. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non- small-cell lung cancer: AVAiL. J Clin Oncol 2009, 27(8):1227-1234.
8. Ferrara N Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications. Semin Oncol 2002, 29:10-14.
9. EMEA. Press Release: Meeting highlights from the Committee for Medicinal Products for Human Use, 22 25 June 2009.
10. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26(21):3543-3551.
11. EMEA. Press release (pemetrexed) Meeting highlights from the Committee for Medicinal Products for Human Use, 26 29 May 2009. EMEA/CHMP/330580/2009.
12. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005, 9:1-134. iii iv.
13. CADTH. Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis. 2009.
14. Bucher HC, Guyatt GH, Griffith LE, Walter SD The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997, 50(6):683-691.
15. Song F, Altman DG, Glenny AM, Deeks JJ Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003, 326(7387):472.
16. Sonnenberg FA, Beck JR Markov models in medical decision making. Med Decision Making 1993, 13:322-338.
17. Nuijten MJC, McCormick J, Waibel F, Parison D Economic evaluation of letrozole in the treatment of advanced breast cancer in post-menopausal women in Canada. Value in Health 2000, 3(1):31-39.
18. Nuijten MJC, Meester L, Waibel F, Wait S Cost-effectiveness of letrozole in the treatment of advanced breast cancer in post-menopausal women in the UK. PharmacoEconomics 1999, 16(4):379-397.
19. Alexander RJ, Herbst RS Expert insight into: new guidelines in the treatment of non-small-cell lung cancer (NSCLC). The Advanced Certificate Program: Lung Cancer Management last accessed 07.05.2009). http://www.projectsinknowledge.com/cp/Activity/index.cfm?jn=1868&sj=1871.01.
20. Collins R, Fenwick E, Trowman R, Perard R, Norman G, Light K, et al. A systematic review and economic model of the clinical effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol Assess 2007, 11(2).
21. Mickisch GH, Schwander B, Walzer S Metastatic renal cell carcinoma: a comparative effectiveness assessment of first-line bevacizumab + interferon alpha-2A vs sunitinib. EJC Suppl 2009, 7(2):437.
22. Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess 2007, 11(40).
23. NICE. Updated Guide to the Methods of Technology Appraisal June 2008. ISBN: 1-84629-741-9.
24. Deeks JJ Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med 2002, 21:1575-1600.
25. Ciuleanu TE, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374(9699):1432-1440.